NONANTIBIOTICS ENHANCE THE ANTIBACTERIAL ACTIVITY OF CEFTRIAXONE AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i11.21535Keywords:
Antibacterial activity, Ceftriaxone, Combination index interpretation, MebeverineHcl, TroxipideAbstract
Objectives: Antibiotic resistance is one of the most persistent issues worldwide nowadays, and methicillin-resistant Staphylococcus aureus (MRSA) infection is one such issue where the standard therapeutic procedures involving powerful antibiotics have failed in controlling the infection.
Methods: In the present study, the antibacterial potency of the nonantibiotics troxipide (TR), mebeverine hydrochloride (Hcl), and their combinations with ceftriaxone (CEF) against MRSA has been investigated using microbiological assays of microplate dilution method and combination index interpretations of the nonantibiotics with β-lactam antibiotic CEF and the zone of inhibition method.
Results: The nonantibiotics ME and TR inhibited resistant strain tested in vitro in the checkerboard assay, where the results showed that CEF and TR exhibited minimum inhibitory concentration (MIC) at concentrations of 50 μg/ml and 318 μg/ml, respectively. Interestingly, CEF when combined with TR reduced the MIC to 8 μg/ml and 78 μg/ml. According to the results, CEF with TR exhibited synergistic interactions at the fractional inhibitory concentration of 0.36–1.4. ME and TR and its combinations, CEF with ME, and CEF with TR have considerable anti-MRSA efficacy, with synergism though at 36 h of incubation.
Conclusion: ME and TR being antispasmodic and antiulcer drugs can also be used against MRSA infections, which could prove to be favorable in the reduction of dosage of antibiotics such as CEF, and cutting down the need for additional administration of antibiotics to the patients affected with multiple complications such as gastrointestinal ulcer, spasm difficulties, and infection.
Downloads
References
Levy SB. The Antibiotic Paradox: How the Misuse of Antibiotics Destroys their Curative Powers. 2nd ed. Cambridge, MA: Perseus Publishing, Cambridge; 2002. p. 353.
Martins M, Dastidar SG, Fanning S, Kristiansen JE, Molnar J, Pagès JM, et al. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant gram-negative infections: Mechanisms for their direct and indirect activities. Int J Antimicrob Agents 2008;31:198-208.
Alanis AJ. Resistance to antibiotics: Are we in the post-antibiotic era? Arch Med Res 2005;36:697-705.
Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H, et al. Meticillin-resistant Staphylococcus aureus (MRSA): Global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents 2012;39:273-82.
Christine L. Case. Discover a New Antibiotic; 1998.
Dutta NK, Annadurai S, Mazumdar K, Dastidar SG, Kristiansen JE, Molnar J, et al. Potential management of resistant microbial infections with a novel non-antibiotic: The anti-inflammatory drug diclofenac sodium. Int J Antimicrob Agents 2007;30:242-9.
Mazumdar K, Dastidar SG, Park JH, Dutta NK. The anti-inflammatory non-antibiotic helper compound diclofenac: An antibacterial drug target. Eur J Clin Microbiol Infect Dis 2009;28:881-91.
Kristiansen JE. Antimicrobial activity of non-antibiotics. ASM News 1991;57:135-9.
Busri A, Puspitawati R, Utami S. Antibacterial effect of java turmeric ethanol extract against dual-species Streptococcus mutans and Streptococcus sanguinis biofilm (in vitro). Asian J Pharm Clin Res 2017;10:57-60.
Sukandar EY, Kurniati NF, Wikaningtyas P, Agprikani D. Antibacterial interaction of combination of ethanolic extract of Zingiber officinale var Rubrum rhizome, Boesenbergia pandurata rhizome and Stevia rebaudiana leaves with certain antibiotics against infectious mouth microbial. Asian J Pharm Clin Res 2016;9:332-5.
Kumar KA, Ganguly K, Mazumdar K, Dutta NK, Dastidar SG, Chakrabarty AN, et al. Amlodipine: A cardiovascular drug with powerful antimicrobial property. Acta Microbiol Pol 2003;52:285-92.
Mazumdar K, Ganguly K, Kumar KA, Dutta NK, Chakrabarty AN, Dastidar SG, et al. Antimicrobial potentiality of a new non-antibiotic: The cardiovascular drug oxyfedrine hydrochloride. Microbiol Res 2003;158:259-64.
Eumkeb G, Chukrathok S. Synergistic activity and mechanism of action of ceftazidime and apigenin combination against ceftazidime-resistant Enterobacter cloacae. Phytomedicine 2013;20:262-9.
Devi KP, Nisha SA, Sakthivel R, Pandian SK. Eugenol (an essential oil of clove) acts as an antibacterial agent against salmonella typhi by disrupting the cellular membrane. J Ethnopharmacol 2010;130:107-15.
Karak P, Kumar KA, Mazumdar K, Mookerjee M, Dastidar SG. Antibacterial potential of an antispasmodic drug dicyclomine hydrochloride. Indian J Med Res 2003;118:192-6.
Akilandeswari K, Ruckmani K. Antibacterial potentiality of anti-ulcer and anti-spasmodic drugs with selected antibiotics against methicillin-resistant Staphylococcus aureus - In vitro and in silico studies. Bangladesh J Pharmacol 2015;10:875-83.
Dutta NK, Mazumdar K, Seok SH, Park JH. The anti-inflammatory drug diclofenac retains anti-listerial activity in vivo. Lett Appl Microbiol 2008;47:106-11.
Alkuraishy HM. In vitro antibacterial effects of selective histaminic receptor Type 2 blockers: A novel study. Webmed Cent Pharmacol 2011;2:WMC002636.
El-Nakeeb MA, Abou-Shleib HM, Khalil AM, Omar HG, El-Halfawy OM. Reversal of antibiotic resistance in gram-positive bacteria by the antihistaminic azelastine. APMIS 2012;120:215-20.
Shafiq B, Muhi-Eldeen Z, Al-kaissi E, Al-adham IS. Synthesis, structural elucidation and antimicrobial evaluation of 2-{4-(tamino)-2- (but-2-yn-1-yl)}-1, 3 benzothiazole derivatives. Int J Pharm PharmSci 2016;8:189-93.
Dilipkumar P, Vipul S, Desh DP, Roopesh KM. Synthesis, characterization and antimicrobial evaluation of some 1, 2, 4- triazole derivatives. Int J Pharm Pharm Sci 2014;6:213-6.
Tomasz AS, Tomasz A. Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: Evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. J Bacteriol 2005;5:1815-24.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
